A5050466636- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Estrogen and related hormone effects
- Cancer, Hypoxia, and Metabolism
- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatic and Hepatic Oncology Research
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Gestational Trophoblastic Disease Studies
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Advanced Breast Cancer Therapies
- Lung Cancer Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Gastric Cancer Management and Outcomes
- Cancer-related Molecular Pathways
- Pituitary Gland Disorders and Treatments
- PI3K/AKT/mTOR signaling in cancer
- Cancer Mechanisms and Therapy
- MRI in cancer diagnosis
- Cancer, Lipids, and Metabolism
Ospedale San Luigi Gonzaga
2015-2024
University of Turin
2015-2024
Gonzaga University
2022
A. O. Ordine Mauriziano di Torino
2019
Medica (Italy)
2017
Associazione Italiana Di Oncologia Medica
2014
Istituti Ospitalieri di Cremona
1998-2011
University of Verona
2011
Ospedale Sacro Cuore Don Calabria
2011
European Institute of Oncology
2011
Purpose Knowledge of clinical course pancreatic endocrine carcinomas (PECs) is poor. This study aimed to determine the time progression advanced PECs, and identify predictors capable selecting subgroups with higher risk progression. Patients Methods In this multicenter retrospective analysis, patients PECs were enrolled. Staging was according European Neuroendocrine Tumors Society guidelines. Grading based on proliferation index using Ki67 immunohistochemistry. The primary end point...
Abstract Purpose: To investigate the relationship of hypoxia-inducible factor-1α (HIF-1α) tumor expression in predicting response to epirubicin and disease-free survival (DFS) patients with breast cancer enrolled a single institution trial primary anthracycline tamoxifen therapy. Experimental Design: The HIF-1α was assessed by immunohistochemistry 187 T2-4 N0-1 randomized comparing four cycles agent versus + as systemic treatment. All postoperatively received weekly i.v. CMF regimen...
To investigate the activity of letrozole plus/minus oral metronomic cyclophosphamide as primary systemic treatment (PST) in elderly breast cancer patients.One hundred fourteen consecutive women with T2-4 N0-1 and estrogen receptor-positive were randomly assigned to therapy (2.5 mg daily for 6 months) or a combination plus (50 mg/daily an open-labeled, randomized phase II trial. Tumor response was assessed clinically, tumor Ki67 index vascular endothelial growth factor (VEGF) -A levels...
Abstract Purpose: We have shown previously that tumor infiltration by FOXP3+ regulatory T cells (Treg) is associated with increased relapse and shorter survival of patients both in situ invasive breast cancer. Because estrogen regulates Treg numbers mice promotes the proliferation human Tregs, we hypothesized blocking receptor-α signaling would abrogate Tregs be response to hormonal therapy survival. Experimental Design: were quantified samples collected at baseline incisional biopsy after 6...
Abstract Everolimus is a valid therapeutic option for neuroendocrine tumors (NETs); however, data in real-world setting outside regulatory trials are sparse. The aim of this study was to determine everolimus tolerability and efficacy, relation previous treatments, compassionate use program. A total 169 patients with advanced progressive NETs treated were enrolled, including 85 pancreatic (pNETs) 84 nonpancreatic (non-pNETs). Previous treatments included somatostatin analogs (92.9%), peptide...
<h3>Importance</h3> Data about the optimal timing for initiation of peptide receptor radionuclide therapy (PRRT) advanced, well-differentiated enteropancreatic neuroendocrine tumors are lacking. <h3>Objective</h3> To evaluate association upfront PRRT vs chemotherapy or targeted with progression-free survival (PFS) among patients advanced who experienced disease progression after treatment somatostatin analogues (SSAs). <h3>Design, Setting, and Participants</h3> This retrospective,...
We aimed to identify signaling pathways involved in the response and resistance aromatase inhibitor therapy patients with breast cancer.One hundred fourteen women T2-4 N0-1, estrogen receptor (ER) alpha-positive tumors were randomly assigned neoadjuvant letrozole or plus metronomic cyclophosphamide. Twenty-four tumor proteins apoptosis, cell survival, hypoxia, angiogenesis, growth factor, hormone assessed by immunohistochemistry pretreatment samples (eg, caspase 3, phospho- mammalian target...
We assessed the activity and toxicity of XELBEVOCT regimen in patients with metastatic well-to-moderately differentiated neuroendocrine neoplasms (WMD-NEN). Ancillary studies evaluated hypertension, proteinuria, vascular endothelial growth factor (VEGF) polymorphisms predicting progression-free survival (PFS) predictive role serum vitamin D proteinuria onset.This prospective phase 2 study included 45 WMD-NEN arising from various primary sites. The treatment was octreotide long-acting release...
The role of surgery for lung metastases (LM) secondary to colorectal cancer (CRC) remains controversial. bulk evidence is derived from single surgical series, hampering any definitive conclusions. aim this study was compare the outcomes CRC patients with LM submitted those who were not.Data 409 as first advanced disease extracted a database 1,411 patients. Patients divided into three groups: G1, comprised 155 pulmonary and extrapulmonary metastases; G2, 104 only no surgery; G3, 50 surgery.No...
<b><i>Introduction:</i></b> Cabozantinib has been approved by the European Medicine Agency (EMA) for hepatocellular carcinoma (HCC) previously treated with sorafenib. is also being tested in combination immune checkpoint inhibitors frontline setting. Real-life clinical data of cabozantinib HCC are still lacking. Moreover, prognostic factors have not investigated. <b><i>Methods:</i></b> We evaluated and outcome patients who received legal...
Background: The optimal treatment sequencing for advanced, well-differentiated pancreatic neuroendocrine tumors (pNETs) is unknown. We performed a multicenter, retrospective study to evaluate the best sequence in terms of progression-free survival first-line (PFS1) and second-line (PFS2), overall among patients with pNETs. Methods: This multicenter retrospectively analyzed prospectively collected data sporadic pNETs who received at least two consecutive therapeutic lines, evidence...
From 1990 to 1997, 16 consecutive patients with stage III and IVa invasive thymoma were treated in a single institution primary chemotherapy consisting adriamycin (40 mg m–2), cisplatin (50 m–2) administered intravenously on day 1, vincristine (0.6 2 cyclophosphamide (700 4 (ADOC). The courses repeated every 3 weeks. aim was evaluate the impact of this cytotoxic regimen respect response rate, per cent radically resected, time progression overall survival. Two complete responses (one clinical...
The association between tumour shrinkage and reduction in kinetic cell activity after primary chemotherapy human breast cancer is still a matter of investigation. 157 patients with T2-4, N0-1, M0 received consisting either the CMF regimen + tamoxifen (the first consecutive 76 cases) or single agent epirubicin subsequent 81). Ki67, p53, bcl2, c-erbB2 steroid hormone receptors were evaluated immunohistochemically specimens obtained before at surgery. Tumour >50% occurred 72.4% patients. Ki67...
The purpose of this study is to investigate the role carbonic anhydrase IX (CAIX) expression in predicting response epirubicin and disease-free survival (DFS) breast cancer patients enrolled a single institution trial primary anthracycline tamoxifen therapy. CAIX was assessed 183 with T2–4 N0–1 randomized comparing four cycles agent versus + as systemic treatment. All received postoperatively weekly i.v. cyclophosphamide, methotrexate, 5-fluorouracil regimen. Patients estrogen receptor...
Well-differentiated neuroendocrine carcinomas are highly vascularized and may be sensitive to drugs administered on a metronomic schedule that has shown antiangiogenic properties. A phase II study was designed test the activity of protracted 5-fluorouracil (5FU) infusion plus long-acting release (LAR) octreotide in patients with carcinoma.Twenty-nine metastatic or locally advanced well-differentiated carcinoma were treated 5FU intravenous (200 mg/m2 daily) LAR (20 mg monthly). Patients...
<b><i>Background:</i></b> Knowledge of clinical course in advanced jejunoileal neuroendocrine tumors (NETs) is poor. <b><i>Aim:</i></b> To investigate progression-free survival (PFS), overall (OS), and possible predictors for disease progression (DP) NETs. <b><i>Patients Methods:</i></b> We carried out a multicenter, retrospective analysis incoming patients with sporadic PFS OS were assessed by Kaplan-Meier analysis....
Abstract Purpose To evaluate the antiproliferative activity and safety of nonconventional high doses somatostatin analogs (HD-SSA) in patients with well-differentiated gastroenteropancreatic (GEP) neuroendocrine tumors (NET) radiological disease progression according to Response Evaluation Criteria Solid Tumors (RECIST) criteria on a previous treatment. Methods A retrospective analysis prospectively maintained databases from 13 Italian NET-dedicated centers was performed. Main inclusion...
Neuroendocrine Carcinomas (NECs) prognosis is poor.No standard second-line therapy currently recognized after failure of platinum-based first-line treatment. FOLFIRI and CAPTEM regimens have shown promising activity in preliminary studies. We aimed to evaluate these metastatic NEC patients.
Abstract Purpose: The phosphatidylinositol 3′-kinase (PI3K)/AKT/molecular target of rapamycin (mTOR) pathway is involved in the development tumor resistance to endocrine therapy breast cancer cell lines and represents an attractive for pharmacologic intervention. However, effects with aromatase inhibitors on vivo expression this signaling cascade, its relation response patient outcome, unknown. Experimental Design: PI3K, phospho-AKT (pAKT) phospho-mTOR were assessed by immunohistochemistry...